Titan Pharmaceuticals, Inc. (AMEX:TTP) announced initial analyses show that SpheramineŽ did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up.
E-Mail this Story
Titan Pharmaceuticals, Inc. (AMEX:TTP) announced initial analyses show that SpheramineŽ did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up.
